Macroprolactin does not contribute to elevated levels of prolactin in patients on renal replacement therapy

Yavuz, Dilek; Topçu, Güler; Özener, Çeti̇n; Akalın, Sema; Sirikci, Onder

doi:10.1111/j.1365-2265.2005.02375.x

Cited by 44 publications

(26 citation statements)

References 21 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These colleagues found hyperprolactinemia in 58% of the individuals (81% of those on hemodialysis, 80% of those on chronic ambulatory peritoneal dialysis and 40% of those with a renal graft). The authors concluded that hyperprolactinemia in chronic renal failure is related to the declining renal function rather than to the presence of prolactin isoforms, such as macroprolactin [29]. In support of these data, our study indicates that elevated prolactin concentrations can be found in almost all hemodialysis patients, and more than 90% of hyperprolactinemic individuals do not show significant amounts of macroprolactin in their serum.…”

Section: Discussionsupporting

confidence: 79%

“…Most recently Yavuz et al [29] investigated hyperprolactinemia and the presence of macroprolactin in 91 patients with chronic kidney disease (CKD; 31 on chronic hemodialysis, 30 on chronic ambulatory peritoneal dialysis and 30 with a renal graft). These colleagues found hyperprolactinemia in 58% of the individuals (81% of those on hemodialysis, 80% of those on chronic ambulatory peritoneal dialysis and 40% of those with a renal graft).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

No Associations between Prolactin Concentrations and Response to Erythropoiesis-Stimulating Agents in Hemodialysis Patients

et al. 2007

View full text Add to dashboard Cite

Background: The effect of serum prolactin levels on the response to erythropoiesis-stimulating agents (ESA) in patients on chronic hemodialysis is unknown. Methods: We included 111 stable hemodialysis patients in this study and examined the association of serum prolactin concentrations with the response to ESA. Accordingly we implemented an ESA index as a measure of therapeutic efficacy. The two outcomes of this cohort study were the association of prolactin concentrations with response to ESA, both at baseline (cross-sectional component) and after 1-year of follow-up (prospective component), and the presence of macroprolactin. Results: Two male patients, but none of the female patients, had serum prolactin concentrations within the reference range. Following precipitation with polyethylene glycol (PEG), 17 males (25.4%) and 9 females (20.6%) had serum prolactin concentrations within the reference range. Females had somewhat higher levels than males: 39.8 (IQR 32.3–64.5) versus 27.8 (IQR 23.4–47.8) ng/ml (p = 0.003). The ratio of prolactin_PEG/prolactin_Native was greater than 0.60 in 103 patients (92.8%), thus excluding significant amounts of macroprolactin. From uni- and multivariate analyses we did not find associations of serum prolactin concentrations with a response to ESA either at baseline or at follow-up. Conclusions: From this prospective study we provide evidence that elevated serum prolactin levels are not related to the presence of macroprolactin in chronic hemodialysis patients. Furthermore, serum prolactin concentrations are not associated with the response to erythropoietic therapy in these individuals.

show abstract

Section: Discussionsupporting

confidence: 79%

Section: Discussionmentioning

confidence: 99%

No Associations between Prolactin Concentrations and Response to Erythropoiesis-Stimulating Agents in Hemodialysis Patients

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Chronic renal failure is associated with an increase in prolactin concentrations (24,25). Decreased clearance and increased production are responsible for the elevation of prolactin in CKD (26).…”

Section: Discussionmentioning

confidence: 99%

Prevalence of subnormal testosterone concentrations in men with type 2 diabetes and chronic kidney disease

Dhindsa

Reddy

Karam³

et al. 2015

European Journal of Endocrinology

View full text Add to dashboard Cite

Background: One-third of men with type 2 diabetes have subnormal testosterone concentrations along with inappropriately normal LH and FSH concentrations. It is not known if the presence of renal insufficiency affects free testosterone concentrations in men with type 2 diabetes. Hypothesis: We hypothesized that type 2 diabetic men with chronic renal disease (CKD; estimated glomerular filtration rate (eGFR) !60 ml/min per 1.73 m 2 ) have lower free testosterone concentrations than men with normal renal function

show abstract

“…However, the role of prolactin in men remains unclear. In CKD, prolactin levels appear substantially elevated, with a prevalence of hyperprolactinemia ranging from 30% to 65% (5)(6)(7). Hyperprolactinemia in CKD is the consequence of both reduced renal clearance (7) and increased production (8,9).…”

Section: Introductionmentioning

confidence: 99%

Prolactin Levels, Endothelial Dysfunction, and the Risk of Cardiovascular Events and Mortality in Patients with CKD

Carrero

Kyriazis

Sönmez

et al. 2012

Clinical Journal of the American Society of Nephrology

110

View full text Add to dashboard Cite

SummaryBackground and objectives Both prolactin clearance and production are altered in CKD. In nonrenal populations, emerging evidence suggests that prolactin participates in the atherosclerotic process. Given the elevated cardiovascular risk of CKD, this study examined links between prolactinemia, vascular derangements, and outcomes.Design, setting, participants, & measurements This observational study was conducted in two cohorts: one with 457 nondialyzed CKD patients (mean age 52612 years; 229 men) with measurements of flow-mediated dilation (FMD) and carotid intima-media thickness and one with 173 hemodialysis patients (65612 years; 111 men) with measurements of pulse wave velocity (PWV). Patients were followed for cardiovascular events (n=146, nondialyzed cohort) or death (n=79, hemodialysis cohort).Results Prolactin levels increased along with reduced kidney function. Prolactin significantly and independently contributed to explain the variance of both FMD (in nondialyzed patients) and PWV (in hemodialysis patients), but not intima-media thickness. In Cox analyses, the risk of cardiovascular events in nondialyzed patients increased by 27% (hazard ratio [HR], 1.27; 95% confidence interval [95% CI], 1.17-1.38) for each 10 ng/ml increment of prolactin. Similarly, the risk for all-cause and cardiovascular mortality in hemodialysis patients increased by 12% (HR, 1.12; 95% CI, 1.06-1.17) and 15% (HR, 1.15; 95% CI, 1.08-1.21), respectively. This was true after multivariate adjustment for confounders and after adjustment within the purported causal pathway (FMD or PWV).Conclusions Prolactin levels directly associated with endothelial dysfunction/stiffness and with increased risk of cardiovascular events and mortality in two independent cohorts of CKD patients.

show abstract

Macroprolactin does not contribute to elevated levels of prolactin in patients on renal replacement therapy

Abstract: The hyperprolactinaemia seen in renal replacement therapy is not associated with the presence of macroprolactin isoforms but with the decline in renal function.

Cited by 44 publications

References 21 publications

No Associations between Prolactin Concentrations and Response to Erythropoiesis-Stimulating Agents in Hemodialysis Patients

No Associations between Prolactin Concentrations and Response to Erythropoiesis-Stimulating Agents in Hemodialysis Patients

Prevalence of subnormal testosterone concentrations in men with type 2 diabetes and chronic kidney disease

Prolactin Levels, Endothelial Dysfunction, and the Risk of Cardiovascular Events and Mortality in Patients with CKD

Contact Info

Product

Resources

About